Health ❯ Healthcare ❯ Regulatory Affairs ❯ FDA Approvals

Label Expansions

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial

Full results will be unveiled Nov. 8 at the AHA meeting to guide payer coverage and prescribing.